MUMBAI, India, June 22 -- Intellectual Property India has published a patent application (202641069495 A) filed by Mr. Ratheesh Kumar Radhakrishnan on June 03, 2026, for A Causal Inference-Driven Artificial Intelligence Platform For Personalized Immunotherapy Response Prediction And Treatment Optimization In Oncology.
Inventor includes Mr. Ratheesh Kumar Radhakrishnan.
The application for the patent was published on June 12, 2026, under issue no. 24/2026.
Abstract: The present system discloses a Causal Multi-Modal Immunotherapy Response Prediction and Optimization Method (CMIRPOM) implemented through a causal inference-driven artificial intelligence platform for personalized cancer immunotherapy. The invention integrates heterogeneous biomedical data, including genomic, transcriptomic, proteomic, tumor microenvironment, and clinical datasets, to generate comprehensive patient-specific representations. An Adaptive Multi-Modal Fusion Technique (AMMFT) dynamically combines biological features, while a Graph Neural Network-Based Causal Modeling Technique (GNN-CMT) constructs causal graphs representing interactions among molecular entities, immune responses, treatments, and outcomes. A Counterfactual Treatment Outcome Simulation Technique (CTOST) evaluates hypothetical therapeutic interventions and predicts response probability, resistance risk, toxicity likelihood, and survival outcomes. The platform further employs an Explainable Causal Attribution Technique (ECAT) to identify key biomarkers and biological pathways influencing treatment response. Additionally, a Continuous Causal Learning and Model Adaptation Technique (CCLMAT) updates predictive models using real-world clinical outcomes, enabling accurate, interpretable, and optimized immunotherapy decision support
Disclaimer: Curated by HT Syndication.
